<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The recognition that the increase of plasma <z:chebi fb="0" ids="17855">triglyceride</z:chebi> rich <z:chebi fb="2" ids="6495">lipoproteins</z:chebi> (TRLs) is associated with multiple alterations of other <z:chebi fb="2" ids="6495">lipoproteins</z:chebi> species that are potentially atherogenic has expanded the picture of diabetic <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The discovery of <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> within major <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> classes <z:chebi fb="1" ids="39027">VLDL</z:chebi>, <z:chebi fb="15" ids="39026">LDL</z:chebi> and <z:chebi fb="17" ids="39025">HDL</z:chebi> opened new avenues to reveal the specific pertubations of diabetic <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The increase of large <z:chebi fb="1" ids="39027">VLDL</z:chebi> 1 particles in Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> initiates a sequence of events that generates atherogenic remnants, small dense <z:chebi fb="15" ids="39026">LDL</z:chebi> and small dense <z:chebi fb="17" ids="39025">HDL</z:chebi> particles </plain></SENT>
<SENT sid="3" pm="."><plain>Together these components comprise the atherogenic <z:chebi fb="23" ids="18059">lipid</z:chebi> triad </plain></SENT>
<SENT sid="4" pm="."><plain>Notably the malignant nature of diabetic <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e> is not completely shown by the <z:chebi fb="23" ids="18059">lipid</z:chebi> measures used in clinical practice </plain></SENT>
<SENT sid="5" pm="?"><plain>The key question is what are the mechanisms behind the increase of <z:chebi fb="1" ids="39027">VLDL</z:chebi> 1 particles in diabetic <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Despite the advances of recent years, our understanding of <z:chebi fb="1" ids="39027">VLDL</z:chebi> assembly and secretion is still surprisingly incomplete </plain></SENT>
<SENT sid="7" pm="."><plain>To date it is still unclear how the liver is able to regulate the amount of <z:chebi fb="4" ids="17855">triglycerides</z:chebi> incorporated into <z:chebi fb="1" ids="39027">VLDL</z:chebi> particles to produce either <z:chebi fb="1" ids="39027">VLDL</z:chebi> 1 or <z:chebi fb="1" ids="39027">VLDL</z:chebi> 2 particles </plain></SENT>
<SENT sid="8" pm="."><plain>The current evidence suggests that the machinery driving <z:chebi fb="1" ids="39027">VLDL</z:chebi> assembly in the liver includes (i) low insulin signalling via PI-3 kinase pathway that enhances <z:chebi fb="23" ids="18059">lipid</z:chebi> accumulation into "nascent " <z:chebi fb="1" ids="39027">VLDL</z:chebi> particles (ii) up-regulation of SREBP-1C that stimulates de novo lipogenesis and (iii) excess availability of "polar molecules" in hepatocytes that stabilizes apo B 100 </plain></SENT>
<SENT sid="9" pm="."><plain>Recent data suggest that <z:hpo ids='HP_0000001'>all</z:hpo> these steps could be fundamentally altered in Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> explaining the overproduction of <z:chebi fb="1" ids="39027">VLDL</z:chebi> apo B as well as the ability of insulin to suppress <z:chebi fb="1" ids="39027">VLDL</z:chebi> 1 apo B production in Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="10" pm="."><plain>Recent discoveries have established the transcription factors including PPARs, SREBP-1 and LXRs as the key regulators of <z:chebi fb="23" ids="18059">lipid</z:chebi> assembly in the liver </plain></SENT>
<SENT sid="11" pm="."><plain>These observations suggest these factors as a new target to tailor more efficient drugs to treat diabetic <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e> </plain></SENT>
</text></document>